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Docetaxel in a Phase III Study (V-15-32) in Advanced
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Haiyi Jiang, MD,§ Yohji Itoh, PhD,§ Nagahiro Saijo, MD, PhD, and Masahiro Fukuoka, MD, PhD
Introduction: This post hoc analysis investigated the relationship
between tumor response and overall survival (OS) in pretreated
advanced non-small cell lung cancer (NSCLC).
Methods: We conducted landmark survival analyses of V-15-32, a
phase III study comparing gefitinib with docetaxel in pretreated
advanced NSCLC. Best response at weeks 8, 12, 16, and 20, and
visit response at week 4, were evaluated.
Results: Disease control (DC; complete response [CR], partial
response [PR], or stable disease) was a better predictor of OS than
CR/PR at all time points. The strongest predictor of OS for both
gefitinib and docetaxel was DC at week 8 (hazard ratio [HR] DC
versus non-DC: 0.30, 95% confidence interval [CI] 0.20–0.45, p 
0.001 for both treatments). DC at week 4 was also associated with
longer survival compared with non-DC for both treatments (HR
0.33, 95% CI 0.23–0.49, p  0.001 for gefitinib; HR 0.30, 95% CI
0.19–0.47, p  0.001 for docetaxel).
Discussion: DC is a better predictor of OS with gefitinib and
docetaxel than CR/PR in advanced pretreated NSCLC, with a best
response of DC at week 8 the strongest predictor.
Key Words: Docetaxel, Epidermal growth factor receptor tyrosine
kinase inhibitors, Gefitinib, Landmark analysis, NSCLC.
(J Thorac Oncol. 2010;5: 1042–1047)
Patients with advanced/metastatic non-small cell lung can-cer (NSCLC) have a poor prognosis, with less than 10%
of patients experiencing tumor shrinkage equating to a com-
plete response or partial response (CR or PR) with standard
second-/third-line chemotherapy.1–4 However, many patients
do achieve nonprogression or disease control (DC; the sum of
CR, PR, and stable disease [SD]), with approximately 35 to
45% of patients achieving SD in clinical trials.1–4 In the
setting of advanced NSCLC, SD may be a positive therapeu-
tic outcome, with potential benefits including improved qual-
ity of life and prolonged survival.5,6 In a prospective,
randomized study of erlotinib in advanced NSCLC after
first-/second-line chemotherapy, there was significant pro-
longation of survival with erlotinib compared with placebo
(6.7 versus 4.7 months, respectively; hazard ratio [HR]
0.61, p  0.001), despite a response rate of 10%; one
possible explanation for this is that a high proportion of
patients had SD during therapy and this may have contrib-
uted to the prolongation in survival.4 In clinical trials,
response based on the Response Evaluation Criteria in
Solid Tumors (RECIST) is widely used to identify and
quantify the antitumor activity of new agents, providing a
relatively quick assessment of efficacy; however, its value
as a predictor of a survival benefit remains unclear.7
Based on the fact that many more patients initially
achieve nonprogression than CR or PR, Lara et al.8 first
hypothesized that the rate of nonprogression, or DC, is a
stronger predictor of clinical benefit than CR/PR after plati-
num-based chemotherapy in patients with advanced NSCLC.
In a pooled analysis of data from 984 patients with advanced
NSCLC who entered into three randomized trials of first-line
platinum-based chemotherapy, landmark survival analysis
showed that DC versus non-DC at week 8 was a stronger
predictor of longer survival (HR 0.45, p  0.0001) than the
traditional CR/PR versus non-CR/PR (HR 0.61, p  0.001).
A study conducted using landmark analysis also found that a
decrease or no change in tumor size at week 8 was signifi-
cantly associated with longer survival (p  0.043) in patients
with advanced NSCLC who received first-line chemotherapy
in the Four-Arm Cooperative Study or pemetrexed as salvage
therapy for previously treated disease.9 A meta-analysis of
the published literature that included 28 phase II/III trials in
6171 patients with advanced NSCLC receiving gefitinib or
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erlotinib found a significant correlation between both re-
sponse rate and DC with survival (p 0.0001 and p 0.003,
respectively).10
Gefitinib is an orally bioavailable, epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitor and was the
first molecular-targeted drug approved for NSCLC. A recent
large international phase III study (IRESSA NSCLC Trial
Evaluating REsponse and Survival versus Taxotere) compar-
ing gefitinib and docetaxel in 1466 patients with pretreated (at
least one platinum-based regimen) advanced NSCLC estab-
lished noninferior survival of gefitinib compared with do-
cetaxel (HR 1.02, 96% confidence interval [CI] 0.91–1.15;
noninferiority margin 1.154).11 A similar phase III study,
V-15-32, compared gefitinib with docetaxel in 489 patients in
Japan with advanced NSCLC who had failed one or two
chemotherapy regimens.12 Noninferiority in overall survival
(OS) was not proven (HR 1.12, 95.24% CI 0.89–1.40; non-
inferiority margin 1.25), although there was no significant
difference in OS (p  0.330) or in progression-free survival
between treatments. The objective response rate was 22.5%
in the gefitinib group and 12.8% in the docetaxel group (odds
ratio 2.14, 95% CI 1.21–3.78, p  0.009). Gefitinib also
significantly improved quality of life versus docetaxel and
was associated with a lower incidence of grade 3/4 adverse
events (40.6% versus 81.6%, respectively).
The aim of this post hoc landmark analysis was to
assess the relationship between tumor response and OS in
Japanese patients with advanced, previously treated NSCLC
who received gefitinib or docetaxel in the V-15-32 study.
PATIENTS AND METHODS
The methodology and overall study results for V-15-32
(clinicaltrials.gov identifier NCT00252707) have been re-
ported in full previously.12 Tumor responses were assessed by
RECIST13 at baseline, every 4 weeks for the first 24 weeks,
and every 8 weeks thereafter.
Two types of objective tumor response were assessed:
visit response (CR/PR, SD, or progressive disease [PD]) at
week 4 and best overall response (CR/PR, SD, or PD) up to
weeks 8, 12, 16, and 20. In the analysis of best response,
patients who eventually had a CR/PR but not by the time
point were classified as having SD; patients who eventually
had SD but not by the time point (because of missing values
or being not evaluable [NE]) were classified as NE. PD
included “symptomatic deterioration.” For the purposes of
the analyses reported here, DC was defined as CR/PR/SD
where SD is defined as SD lasting 6 weeks after random-
ization, instead of 12 weeks used in the previous report.12
In the analysis of visit response at week 4, CR/PR/SD were
TABLE 1. Landmark Analysis of Overall Survival by Best Response up to Weeks 8, 12, 16, and 20, and Visit Response at Week
4 (Evaluable for Response Population)
Treatment Week Statistics
Evaluable
for
Response
Best Response
a
Comparison
CR/PR SD PD
Survival HR (95% CI), p
CR/PR vs. non-
CR/PR DC vs. non-DC
Best response analysis
Gefitinib 8 No. of patients (%) 182 (91.0) 28 (14.0) 52 (26.0) 102 (51.0) 0.55 (0.31–0.96) 0.30 (0.20–0.45)
No. of deaths 119 14 23 82 0.034 0.001
12 No. of patients (%) 173 (86.5) 40 (20.0) 42 (21.0) 91 (45.5) 0.44 (0.26–0.73) 0.32 (0.22–0.48)
No. of deaths 109 17 20 72 0.002 0.001
16 No. of patients (%) 160 (80.0) 42 (21.0) 40 (20.0) 78 (39.0) 0.47 (0.28–0.80) 0.36 (0.23–0.54)
No. of deaths 95 17 19 59 0.005 0.001
20 No. of patients (%) 151 (75.5) 45 (22.5) 37 (18.5) 69 (34.5) 0.46 (0.27–0.78) 0.40 (0.26–0.62)
No. of deaths 86 17 19 50 0.004 0.001
Docetaxel 8 No. of patients (%) 173 (92.5) 8 (4.3) 71 (38.0) 94 (50.3) 0.64 (0.24–1.75) 0.30 (0.20–0.45)
No. of deaths 107 4 29 74 0.386 0.001
12 No. of patients (%) 170 (90.9) 18 (9.6) 64 (34.2) 88 (47.1) 0.35 (0.15–0.79) 0.33 (0.22–0.50)
No. of deaths 104 6 30 68 0.012 0.001
16 No. of patients (%) 160 (85.6) 21 (11.2) 61 (32.6) 78 (41.7) 0.49 (0.25–0.98) 0.37 (0.25–0.57)
No. of deaths 94 9 27 58 0.044 0.001
20 No. of patients (%) 150 (80.2) 24 (12.8) 57 (30.5) 69 (36.9) 0.54 (0.28–1.05) 0.41 (0.27–0.63)
No. of deaths 84 10 25 49 0.070 0.001
Visit response analysis
Gefitinib 4 No. of patients (%) 172 (86.0) 33 (16.5) 83 (41.5) 56 (28.0) 0.44 (0.26–0.76) 0.33 (0.23–0.49)
No. of deaths 114 15 52 47 0.003 0.001
Docetaxel 4 No. of patients (%) 156 (83.4) 11 (5.9) 105 (56.1) 40 (21.4) 0.85 (0.37–1.94) 0.30 (0.19–0.47)
No. of deaths 92 6 54 32 0.695 0.001
HR 1 implies a lower risk of death for those patients with CR/PR vs. non-CR/PR or DC vs. non-DC.
aVisit response for week 4.
CI, confidence interval; CR, complete response; DC, disease control (CR, PR, or SD); HR, hazard ratio; PD, progressive disease; PR, partial response; SD, stable disease.
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defined according to RECIST (tumor shrinkage) without
considering the duration of each status. In the analysis of visit
response at week 4, if a patient was judged as “symptomatic
deterioration” before the time window of week 4 defined in
the protocol (25–31 days), it was assumed to occur at week 4.
Landmark analysis is a valid method of comparing
survival by response category14 and determines each patient’s
response at a fixed time point, with survival estimates calcu-
lated from that time point and associated statistical tests being
conditional on patients’ landmark responses. Patients who die
before the landmark time point are excluded from the anal-
ysis. In this study, landmark analysis was performed to assess
the associations of best response and visit response outcomes
with OS in the evaluable for response population (defined as
patients with 1 measurable lesion at baseline by RECIST),
excluding NE patients. Separate Cox regression models for
each treatment group and time point in patients in the evalu-
able for response population who were alive at the response
assessment time point were used to determine HRs for com-
paring response groups (CR/PR versus non-CR/PR, DC ver-
sus non-DC).
RESULTS
The evaluable for response population included 200
patients randomized to gefitinib and 187 patients randomized
to docetaxel.
At each time point (best response at weeks 8, 12, 16,
and 20), and for both treatments, survival was significantly
longer among patients with DC compared with non-DC
(Table 1). Similarly, survival was longer among patients with
CR/PR compared with non-CR/PR. However, DC was a
stronger predictor of survival than CR/PR, with smaller HRs
for both treatments at all time points. The HR of DC versus
non-DC was smallest at week 8 than at later time points in
both treatment groups (HR 0.30, 95% CI 0.20–0.45,
p0.001 with both gefitinib and docetaxel). Both CR/PR and
SD as best response at week 8 were associated with longer
survival times compared with PD for both gefitinib and
docetaxel (Figure 1), although the docetaxel data are harder
to interpret because of the small number of responders. In the
gefitinib group, OS was similar among patients with CR/PR
and those with SD as their best response at week 8 (Figure
FIGURE 1. Overall survival by best response up
to week 8 after treatment with (A) gefitinib or (B)
docetaxel (evaluable for response population).
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1A). With both treatments, survival in patients with SD by
week 8 tracked closer to survival in patients with CR/PR than
to those with PD. A similar pattern of results was obtained by
best response at weeks 12, 16, and 20 (data not shown).
Consistent with the findings for best response at later
time points, at week 4, a visit response of DC was associated
with longer survival compared with non-DC for both gefitinib
and docetaxel, with smaller HRs than CR/PR versus non-
CR/PR (Table 1). The magnitude of effect was similar at
week 4 (visit response analysis) to week 8 (best response
analysis) (gefitinib HRs of 0.33 [week 4] and 0.30 [week 8];
docetaxel HRs of 0.30 [week 4] and 0.30 [week 8]). In both
treatment groups, the Kaplan-Meier survival curves for pa-
tients with CR/PR and for those with SD were separated from
those with PD by visit response at week 4 (Figure 2). In the
gefitinib group, there was also some separation in the survival
curves between the CR/PR and SD subgroups at week 4. This
was difficult to assess for the docetaxel group because of the
small number of responders.
Comparing visit response at week 4 to best response at
week 8 shows that most patients with a best response of
CR/PR at week 8 also had a visit response of CR/PR at week
4 (27 of 28 [96%] on gefitinib; 8 of 8 [100%] on docetaxel).
Similarly most patients with a best response of DC at week 8
also had a visit response of DC at week 4 (75 of 80 [94%] on
gefitinib, 78 of 79 [99%] on docetaxel) (Table 2). Of those
patients with a visit response of DC at week 4, 75 of 116
(65%) on gefitinib and 78 of 116 (67%) on docetaxel main-
tained DC at week 8.
DISCUSSION
In this landmark survival analysis of data from a single
randomized phase III study, we found that DC was a better
predictor of OS than CR/PR at all time points in previously
treated Japanese patients with advanced NSCLC. The stron-
gest predictor of OS for both gefitinib and docetaxel was DC
as best response at week 8. Once a patient has PD, survival
outcome is predicted to be markedly poorer than for patients
without PD at that time. In addition, DC and CR/PR at the
week 4 visit were also early predictors of survival for both
gefitinib and docetaxel. Consistent with the later findings at
week 8, DC at week 4 was a stronger predictor of survival
than CR/PR. The strength of the predictive value of DC for
FIGURE 2. Overall survival by visit response at
week 4 after treatment with (A) gefitinib or (B)
docetaxel (evaluable for response population).
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survival was similar at weeks 4 and 8, suggesting that the
visit response at week 4 may potentially be used as an early
predictor of survival.
These results are consistent with those of Lara et al.8
and Yamamoto et al.,9 supporting the concept that week 8 is
a landmark time point for advanced NSCLC patients for
systemic therapy regardless of line of therapy. Lara et al.8
found no substantial new findings from analyses at later time
points (weeks 14 and 20), compared with week 8 of therapy.
However, although in the current analysis visit response at
week 4 was a predictor of survival, as well as best response at
week 8, during second- or third-line treatment with either do-
cetaxel or gefitinib, in our previous analysis of other studies
employing first-line chemotherapy or pemetrexed as salvage
therapy, week 4 was not a landmark time point, with no signif-
icant associations found between response and survival.9
Lara et al.8 also found that DC at week 8 was a better
predictor of survival than CR/PR after platinum-based che-
motherapy in the first-line setting using either Southwest
Oncology Group (modified World Health Organization) tu-
mor response criteria or RECIST to define response.8 In our
earlier landmark analysis, tumor shrinkage rate (defined as a
decrease or no change in tumor size) at week 8 was signifi-
cantly associated with longer survival after first-line plati-
num-based chemotherapy or after salvage therapy with pem-
etrexed.9 It has been suggested that because of the mechanism
of action, it might be more important to achieve SD with
EGFR tyrosine kinase inhibitors such as gefitinib than with
cytotoxic chemotherapy5; however, the relationship between
DC and survival seemed similar for docetaxel and gefitinib in
the current analyses.
EGFR mutation is predictive of outcome to ge-
fitinib15–17 and it would have been interesting to have looked
at the impact of EGFR mutation on our analysis. However, in
this study, data on EGFR mutation were limited due to the
fact that informed consent for tissue collection was obtained
at a very late stage of the study and consequently was
obtained from patients with relatively longer survival. Thus,
biomarker analyses were not performed because analyzing
these samples would have introduced considerable bias.
These data suggest that DC could give an early indica-
tion of OS time; whether this is a true surrogate for OS benefit
is yet to be determined. If proven, DC could be used as a
predictor in early phase development and as a possible end
point in phase II trials. There are also implications for
medical practice, raising the importance of continuing to treat
patients who achieve SD because of the potential survival time;
patients who achieve SD have a survival outcome similar to
those patients with a CR/PR, suggesting that they should remain
on the same treatment rather than switch to an alternative
therapy because they are considered not to have responded to
treatment. Further validation of DC as a predictor or surrogate of
survival benefit in a prospective study is required.
In conclusion, our data suggest that DC is a stronger
predictor of subsequent survival than the traditional CR/PR in
patients receiving second- or third-line gefitinib or docetaxel
for advanced NSCLC, as previously shown for patients who
received first-line platinum-based chemotherapy. These re-
sults suggest that patients with DC should remain on their
current treatment rather than switching. The strongest predic-
tor of OS for both gefitinib and docetaxel was DC as best
response at week 8.
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TABLE 2. Relationship Between Visit Response at Week 4 and Best Response at Week 8
(Evaluable for Response Population)
Treatment
Best Response at Week 8
CR/PR SD PD NE Dead Total
Gefitinib
Visit response at week 4
CR/PR 27 6 0 0 0 33
SD 0 42 39 1 1 83
PD 0 0 53 0 3 56
NE 1 4 10 2 9 26
Dead 0 0 0 0 2 2
Total 28 52 102 3 15 200
Docetaxel
Visit response at week 4
CR/PR 8 1 1 1 0 11
SD 0 69 34 2 0 105
PD 0 0 40 0 0 40
NE 0 1 19 5 5 30
Dead 0 0 0 0 1 1
Total 8 71 94 8 6 187
CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease; NE, not evaluable.
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